Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease
Background/Aims Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract, and encompasses both ulcerative colitis (UC) and Crohn’s disease (CD). Refractory disease is common, a combination of advanced drug therapies may be required to obtain maximal eff...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Korean Association for the Study of Intestinal Diseases
2025-10-01
|
| Серія: | Intestinal Research |
| Предмети: | |
| Онлайн доступ: | http://irjournal.org/upload/pdf/ir-2024-00174.pdf |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|